Beijing SL Pharmaceutical Co Ltd banner
B

Beijing SL Pharmaceutical Co Ltd
SZSE:002038

Watchlist Manager
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Watchlist
Price: 6.49 CNY -3.85% Market Closed
Market Cap: ¥6.7B

P/E

79.6
Current
112%
More Expensive
vs 3-y average of 37.6

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
79.6
=
Market Cap
¥6.6B
/
Net Income
¥83.8m

Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.

P/E
79.6
=
Market Cap
¥6.6B
/
Net Income
¥83.8m

Valuation Scenarios

Beijing SL Pharmaceutical Co Ltd is trading above its 3-year average

If P/E returns to its 3-Year Average (37.6), the stock would be worth ¥3.06 (53% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-63%
Maximum Upside
No Upside Scenarios
Average Downside
54%
Scenario P/E Value Implied Price Upside/Downside
Current Multiple 79.6 ¥6.49
0%
3-Year Average 37.6 ¥3.06
-53%
5-Year Average 29.1 ¥2.38
-63%
Industry Average 49.4 ¥4.03
-38%
Country Average 29.6 ¥2.42
-63%

Forward P/E
Today’s price vs future net income

Today's Market Cap Net Income Forward P/E
¥6.6B
/
Oct 2025
¥83.8m
=
79.6
Current
¥6.6B
/
Dec 2025
¥404.8m
=
16.4
Forward

Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.

Peer Comparison

All Countries
Close
Earnings Growth PEG
CN
B
Beijing SL Pharmaceutical Co Ltd
SZSE:002038
Average P/E: 40
79.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
87.3
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
23
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
19.2
16%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.2
19%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
14%
1.2
NL
argenx SE
XBRU:ARGX
37.4
30%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
AU
CSL Ltd
ASX:CSL
29.5
9%
3.3

Market Distribution

Higher than 78% of companies in China
Percentile
78th
Based on 5 557 companies
78th percentile
79.6
Low
0 — 17.1
Typical Range
17.1 — 57.7
High
57.7 —
Distribution Statistics
China
Min 0
30th Percentile 17.1
Median 29.6
70th Percentile 57.7
Max 43 569.3

Beijing SL Pharmaceutical Co Ltd
Glance View

Market Cap
6.7B CNY
Industry
Biotechnology

Beijing SL Pharmaceutical Co Ltd. is a notable player in the pharmaceutical sector, navigating the rigorous demands of healthcare with a focus on innovation and market responsiveness. Born from a deep understanding of the medical field, the company has carved a niche by focusing on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical products. Among its specialties, Beijing SL Pharmaceutical is renowned for its expertise in producing complex chemicals and biologics, which are vital in treating various medical conditions ranging from cardiovascular diseases to neurological disorders. The company puts significant emphasis on research and development, ensuring that its product pipeline remains robust and poised for future growth. The commercial success of Beijing SL Pharmaceutical is largely driven by its keen adaptation to the dynamic healthcare needs both domestically and internationally. The company leverages its extensive distribution network and strategic partnerships with healthcare providers and institutions to ensure that its products reach patients efficiently. By maintaining a diverse product portfolio that caters to pressing medical needs, the company combines patient-centric strategies with astute business acumen to maintain steady revenue streams. Furthermore, its commitment to quality and safety standards reinforces trust among stakeholders, thereby enabling Beijing SL Pharmaceutical to thrive in a competitive landscape. As it continues to expand, the company remains vigilant in enhancing its technological capabilities and market reach, always with an eye on delivering value through health and wellness.

Intrinsic Value
4.41 CNY
Overvaluation 32%
Intrinsic Value
Price ¥6.49
B
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett